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Neuromyelitis optica (NMO) is an autoimmune
inflammatory disorder of the central nervous
system. In most NMO patients, autoantibodies to
the water channel protein Aquaporin 4 (AQP4) are
present at high levels and are thought to drive
pathology by mediating complement-dependent
destruction of astrocytes. Here, we apply recently
developed chemical library screening technology to
identify a synthetic peptoid that binds anti-AQP4
antibodies in the serum of NMO patients. This finding
validates, in a well-defined human disease, that syn-
thetic, unnatural ligands for the antigen-binding site
of a disease-linked antibody can be isolated by
high-throughput screening.
INTRODUCTION
Neuromyelitis optica (NMO) is a rare, autoimmune demyelinating
disease that can result in blindness and paralysis (Wingerchuk
et al., 2006). A major breakthrough in the understanding of
NMOwas the discovery that most NMOpatients have high levels
of circulating immunoglobulin G (IgG) autoantibodies against
a water channel protein aquaporin 4 (AQP4) (Lennon et al.,
2004) expressed on the surface of astrocytes in the central
nervous system (CNS). There is evidence that these auto-
antibodies fix complement on the surface of certain AQP4-
expressing cells (Crane et al., 2011), resulting in tissue injury
(Papadopoulos and Verkman, 2012). Currently, anti-AQP4 auto-
antibodies may be detected by a variety of methods: ELISA
against recombinant AQP4 protein, tissue-based immunofluo-
rescence, AQP4-transfected cell-based assays, fluorescence
immunoprecipitation assays, and flow cytometric assays (Haya-
kawa et al., 2008; Kalluri et al., 2010; Waters and Vincent, 2008;
Waters et al., 2012). The target epitopes recognized by AQP4
autoantibodies in these assays include determinants on the
three extracellular loops (Iorio et al., 2012; Pisani et al., 2011);
however, the sequence and conformational determinants remain
unresolved due to the use of polyclonal patient serum and the
limited characterization of the AQP4 protein target.Chemistry & Biology 20, 3Despite the high diagnostic specificity of these multiple
assays, approximately 25% (Waters et al., 2012) of patients
with clinical NMO (Wingerchuk et al., 2006) lack readily detect-
able anti-AQP4 antibodies. These patients may have low-titer,
low-affinity anti-AQP4 antibodies or may produce autoanti-
bodies against alternative CNS targets (Lalive et al., 2006).
Misdiagnosis of these patients may lead to unnecessary diag-
nostic studies and inappropriate therapy and highlights the
need for further work on the discovery of biomarkers for the
disease.
We have reported chemical library screening-based tech-
nology for the discovery of diagnostically useful antibodies
(Reddy et al., 2011). In this method, several thousand peptoids
(Simon et al., 1992) (oligo-N-substituted glycines) are arrayed
on chemically modified glass slides. These peptoid arrays
are then exposed to serum from case and control individuals,
followed by a labeled antihuman IgG antibody to visualize the
binding pattern of the serum IgGs. Peptoids that capture high
levels of antibody from the case samples, but not the controls,
are taken as ligands for candidate biomarker antibodies. Note
that this is not a ‘‘fingerprinting’’ analysis of complex patterns
of thousands of spots on the array (Halperin et al., 2011;
Restrepo et al., 2011) but rather a chemical screen to identify
a few ligands for individual IgG antibody biomarkers of high
diagnostic value.Moreover, this approach to antibody biomarker
discovery makes use of unnatural libraries of chemical com-
pounds rather than attempting to screen libraries of candidate
autoantigens such as peptides or proteins (Nagele et al., 2011;
Robinson et al., 2002; Wang et al., 2005). We previously vali-
dated this approach using a mouse model for multiple sclerosis
(MS) and also identified candidate biomarkers for human Alz-
heimer’s Disease (AD) (Reddy et al., 2011) that are currently
undergoing more extensive testing.
Here, we apply this technology to NMO. From the perspective
of validation of this method for biomarker discovery in a human
disease, NMO is an attractive system. One would expect to
isolate peptoids that bind to anti-AQP4 autoantibodies, thus
providing a clear validation of the approach. We show here
that a screen of 100,000 peptoids using a second-generation
bead-based screening approach indeed yielded several peptoid
ligands for the antigen-binding site of anti-AQP4 antibodies. We
show, in a small preliminary study that the use of a small panel of
these peptoids allows one to distinguish between NMO patient51–359, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 351
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narcolepsy, and lupus with high accuracy.
RESULTS
Screening Bead-Displayed Peptoid Libraries for
Antibody Ligands
Our previous report (Reddy et al., 2011) used comparative
screening of several thousand peptoids arrayed on a modified
glass slide against case and control serum samples. In order
to substantially increase the number of compounds that could
be used in such a screen, we first developed a protocol that
allowed one-bead, one-compound (OBOC) libraries synthesized
on hydrophilic TentaGel beads to be used directly in the
screening step. Libraries of hundreds of thousands, or even
millions, of peptoids are easily prepared in this format by split-
and-pool solid-phase synthesis (Alluri et al., 2003; Figliozzi
et al., 1996; Lam et al., 1991), and these libraries can be used
productively in screening experiments using recombinant
proteins (Lim et al., 2007; Xiao et al., 2007) or cells (Lau et al.,
2002; Mikawa et al., 2004; Udugamasooriya et al., 2008) as
targets. The strategy that we envisioned is shown in Figure 1A.
The bead library would first be incubated with a pool of control
serum samples followed, after washing, by a red quantum
dot-labeled secondary antibody to ‘‘light up’’ beads that retain
significant amounts of these uninteresting antibodies or bind
directly to the secondary antibody. After removal of these beads,
the denuded library would then be exposed to a pool of NMO
serum samples and the labeled secondary antibody. Hits from
this screen would be collected as possible ligands for NMO-
specific antibodies and analyzed further (for details, see Experi-
mental Procedures and Supplemental Information available
online). The serum samples used in this study were provided
by the Guthy-Jackson Charitable Foundation and their use was
approved by an Institutional Review Board commissioned by
that organization.
A library of peptoids containing five variable positions after
an invariant linker of four residues was constructed using the
submonomer synthetic method (Zuckermann et al., 1992). Ten
amines were used in the synthesis of the library (Figure 1C),
providing a theoretical diversity of 100,000 compounds. The
linker (Figure 1B) contained a C-terminal methionine residue to
facilitate cyanogen bromide-mediated release of the compound
from the bead after screening, a furan-containing residue to
facilitate postscreening labeling of the compound, and two
lysine-like peptoid residues (Nlys), which are charged at neutral
pH and should aid in the presentation of the peptoid in aqueous
solution.
As described earlier, the library (z100,000 beads) was first
exposed to a pool of six serum samples obtained from control
individuals who do not have NMO, followed by fluorescently
labeled antihuman IgG secondary antibody. Beads that ex-
hibited an obvious fluorescent halo under a low-power fluores-
cence microscope were removed using a micropipette. The
remainder of the library was washed several times with buffer
and then incubated with a pool of six serum samples obtained
from NMO patients whose serum tested positive for comple-
ment-mediated cytotoxicity using AQP4-transfected HEK293
cells, followed by labeled secondary antibody. Beads that352 Chemistry & Biology 20, 351–359, March 21, 2013 ª2013 Elseviedisplayed above-background binding of antibodies as evi-
denced by the red halo (Figure 1D) were picked. To verify that
the beads visualized at this stage are indeed candidate hits,
the binding experiment was redone. After stripping the beads
with 1% SDS, washing extensively to remove the SDS, and re-
equilibrating the beads, the NMO serum pool was reapplied.
After this step, a total of 43 beads were deemed potential hits.
These were segregated into the wells of a microtiter plate. The
peptoids were released into solution by cleavage with CNBr
and sequenced by tandem mass spectrometry (Figure S1).
Initial Characterization of Screening Hits
Due to a variety of complexities with bead-based screening
technology, it is often the case that compounds that appear to
be hits at the bead stage fail to validate in subsequent assays
(Chen et al., 2009). Moreover, in this screen, it is possible that
one of the pooled NMO samples may have had very high levels
of an antibody idiosyncratic to that patient and peptoid ligands
of poor diagnostic utility might be isolated. Therefore, it is imper-
ative to assess the ability of the peptoid hits to distinguish several
individual case and control serum samples on a different analyt-
ical platform. Ten (Table S1) of the 43 hits that corresponded to
the brightest beads at the screening stage were resynthesized
and spotted on to chemically modified glass slides (Lesaicherre
et al., 2002; Reddy and Kodadek, 2005). We also synthesized
a fluorescein-labeled derivative of one of these peptoids,
NMOP6 (NMO Peptoid 6), and used it as a control to ensure
that the spotting process proceeded efficiently. A peptoid that
was found to bind directly to the secondary antibody, NMOP8,
was also spotted on to the array as an internal control. A deriva-
tive of dinitrophenol (DNP), a small molecule that is recognized
by antibodies present in most people, was also spotted as
another control.
The slides were then incubated with individual serum samples
(see Experimental Procedures) and, after washing, fluorescently
labeled secondary antibody. As shown in Figure 2A, when the
array was exposed to serum from a control patient, not suffering
from NMO, there was little signal observed on any of the arrayed
peptoids, except, of course, NMOP8. DNP, as expected, also
registered a strong signal. A strong signal was observed in the
fluorescein channel for the labeled peptoid, confirming that
spotting had proceeded efficiently (data not shown). When the
experiment was repeated with a serum sample obtained from
an NMO patient whose serum tested positive in an assay that
scores the ability of serum antibodies to drive complement-
mediated killing that express recombinant AQP4 (Phuan et al.,
2012), indicating the presence of anti-AQP4 antibodies, strong
signals were observed on NMOP6. When the experiment was
conducted with a sample from an NMO patient that tested nega-
tive for anti-AQP4 antibodies by the cell-killing assay, significant
intensities were observed on NMOP6, NMOP2, NMOP5, and
NMOP9. Note that a negative result in the cell-killing assay
does not mean that the serum does not contain anti-AQP4 anti-
bodies. They could be present at a level that is insufficient to
trigger efficient cell killing in this assay or they could be variants
that do not readily fix complement. Nonetheless, since the inten-
sity of the NMOP6 signal was markedly lower than was the case
for the serum sample that was clearly positive in this assay, it is
possible that this peptoid may be a ligand for anti-AQP4r Ltd All rights reserved
Figure 1. Screening a Combinatorial Peptoid Library for Ligands to NMO-Specific Antibodies
(A) Schematic depiction of the screening strategy. An OBOC library was prescreened with control serum to eliminate the beads that can bind to the antibodies
present at high levels in control (non-NMO) sera. The denuded library was then screened against a pool of NMO serum high in anti-AQP4 antibodies. In both the
prescreen and the NMO screen, antibody-binding beads were visualized using a red quantum dot-conjugated secondary antibody. The hits were identified by
tandem mass spectrometry.
(B) General structure of the 8-mer peptoid in the library used for the screening of NMO sera. The invariant linker is shown in black, and the variable region is shown
in blue, with side-chain substituents (from the amines) shown in red.
(C) List of amines used in the solid-phase synthesis of the library.
(D) A representative photomicrograph of the library under the fluorescent microscope after incubation with the serum followed by hybridization of antihuman
secondary antibody conjugated with Qdot 655. The beads were irradiated through a DAPI filter. The beads with the red halo are the hits.
See also Figure S1.
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vidual NMO serum samples, half of which tested positive in the
cell-killing assay and half of which did not, are shown in Fig-
ure S2. NMOP6 showed strong signals for the NMO sera that
tested positive for cell killing and lower signals for two of the
four NMO samples that tested negative for cell killing. NMOP4,Chemistry & Biology 20, 3NMOP5, and NMOP9 also retained significant amounts of anti-
bodies from certain NMO samples but were dark on others.
The chemical structures of these microarray-validated hits
are shown in Figure 2C. NMOP1, NMOP3, NMOP7, and
NMOP10 failed to provide robust signals in any of the samples.
The structures of all of these peptoids are shown in Table S1.51–359, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 353
Figure 2. Validation of Bead Screening Hits by Microarray Analysis
Results of hybridizing serum samples or purified antibodies to the array, followed by washing and subsequent addition of a red-labeled secondary antibody (see
Experimental Procedures). The screen shots from the microarray scanner are shown.
(A) Analysis of serum samples from a control individual who did not have NMO (Normal) and NMO patients that tested either positive (Anti-AQP4+) or negative
(Anti-AQP4) for complement-mediated cell killing of cells expressing AQP4. As stated in the main text, this does not necessarily mean that the ‘‘anti-AQP4 Ab-’’
samples are devoid of anti-AQP4 antibodies.
(B) Analysis of purified monoclonal anti-AQP4 antibody and control antibody. NMOP8 binds the secondary antibody directly. DNP, dinitrophenol.
(C) Chemical structures of the peptoids that showed significant affinity for NMO-specific antibodies. The structure of the linker is shown in Figure 1.
See also Figures S2 and S3 and Table S1.
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To test the hypothesis that NMOP6 is a ligand for anti-AQP4
antibodies, the array was exposed to a monoclonal antibody
isolated from a patient that binds the full-length M1 isoform of354 Chemistry & Biology 20, 351–359, March 21, 2013 ª2013 Elseviehuman AQP4 (Bennett et al., 2009) or to a control antibody,
called rAb-2B4 that binds the measles virus nucleocapsid and
is of the same isotype (IgG1) as the anti-AQP4 antibody. As
shown in Figure 2B, NMOP6 retained the anti-AQP4 antibodyr Ltd All rights reserved
Figure 3. Peptoid NMOP6 Is an AQP4 Antigen Surrogate
The graph depicts the level of signal on an array for the peptoid and serum samples indicated. MS = multiple sclerosis. The serum samples indicated were either
applied to the array directly or after being incubated with immobilized AQP4 or, as a control, BSA. NMOP6S is a scrambled version of NMOP6. Note that the terms
‘‘anti-AQP4 Ab+’’ and ‘‘anti-AQP4 Ab’’ connote serum samples that tested positive and negative, respectively, in the assay for complement-mediated killing of
AQP4-expressing cells. As stated in themain text, this does not necessarily mean that the anti-AQP4 Ab samples are devoid of anti-AQP4 antibodies. Error bars
indicate the SD from mean; n = 3.
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a specific interaction because a scrambled version of NMOP6
(NMOP6s; see Table S1) was also spotted onto the array. This
peptoid has the same chemical functionality as NMOP6, but
the order of the side chains is scrambled. NMOP6S did not
bind the anti-AQP4 monoclonal antibody, or antibodies from
the serum of NMO patients (Figure 2; Figure S3).
NMOP10 also showed a weak signal for the anti-AQP4 Ab,
indicating that it is likely a very low affinity ligand for this antibody,
but since this peptoid was not of utility in serum screening, this
issue was not pursued further.
To ask in a different way if NMOP6 indeed recognizes anti-
AQP4 antibodies, the serum from an NMO patient was passed
over a column of immobilized recombinant AQP4 or, as
a control, bovine serum albumin (BSA). The depleted serum
was then applied to the array. As shown in Figure 3, the robust
signal observed on NMOP6 for the NMO sample was abol-
ished when the anti-AQP4 antibodies were removed from it,
but the signal was unaffected by passage over a BSA column.
Moreover, the signal on the DNP control spot was unaffected
by passage of the serum over either column, proving that
there was no general depletion of antibodies during the
procedure. The microarray images of the binding pattern of
the sera before and after depletion experiments are shown in
Figure S3. Based on these data and the experiment using
the monoclonal antibody, we conclude that NMOP6 binds
anti-AQP4 antibodies.Chemistry & Biology 20, 3Peptoids NMOP2, NMOP5 and NMOP9 did not retain signifi-
cant amounts of antibodies from the serum sample employed
for the above depletion experiment. But this does not necessarily
mean that they are ligands for antibodies that recognize antigens
other than AQP4. The anti-AQP4 antibody spectrum in any
patient is polyclonal (Iorio et al., 2012). Given that a small mole-
cule like a peptoid is likely to recognize only a fraction of this
polyclonal population, it is possible that NMOP2, NMOP5 and
NMOP9 are ligands for anti-AQP4 antibodies whose epitope
selectivity is different than the antibodies recognized by
NMOP6. Therefore, we repeated the depletion experiment with
another serum sample obtained from an NMOpatient that tested
negative for anti-AQP4 antibodies by the cell-killing assay, but
which showed readily detectable signals on these peptoids.
This is the same serum sample used in the Figure 2 experiment
(second column). As shown in Figure 3, the signals on NMOP2,
NMOP5 and NMOP9 were almost completely abolished by
passage of the serum over immobilized AQP4 protein, similar
to NMOP6. However, approximately 50% of the signal on
these three peptoids was lost when the serum was passed
over immobilized BSA. A reasonable interpretation of these
results is that NMOP2, NMOP5 and NMOP9 are indeed ligands
for anti-AQP4 antibodies that recognize different epitopes than
the antibodies bound by NMOP6, but that these antibodies are
‘‘stickier’’ or more promiscuous in their binding selectivity.
However, this issue will require more experimentation to address
unequivocally.51–359, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 355
Figure 4. Blinded Analysis of 15 Serum Samples
Fifteen serum samples were analyzed in a blinded fashion on arrays of the type
shown in Figure 2. A heat map representing the intensities observed on the
arrays is shown. The samples were called NMO if any of the peptoids (other
than NMOP8, which binds the secondary antibody directly) displayed a clear
signal above background. The calls, made prior to unblinding, are shown in red
at the bottom of the heat map, and the identities of the samples are shown in
black below the calls. C, control; N+, NMO serum that tested positive in the
complement-mediated cell-killing assay; N, NMO serum that tested negative
in the cell-killing assay.
See also Table S2.
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NMOpatients are sometimesmisdiagnosed asMSpatients, with
potentially serious adverse consequences (Uzawa et al., 2010).
Since MS patients lack antibodies to AQP4, we predicted that
the peptoids isolated from the screen would not cross-react
with antibodies from MS patients. As shown in Figure 3, when
serum from three MS patients was hybridized to the array, little
or no signal was observed on any of the peptoids, although the
DNP signal was strong, showing that the peptoids may be useful
in distinguishing these sometimes symptomatically similar
diseases from one another.
Since MS patients are not known to have high levels of auto-
antibodies, we also challenged the peptoid probes with sera
from diseases where autoantibodies have been detected or
are thought to exist. For example, lupus patients are known to
have unusually high levels of autoantibodies. We also examined
sera from patients with narcolepsy, which is believed to be an
autoimmune condition (Hallmayer et al., 2009), and AD, where
disease-related antibodies have been reported (Nagele et al.,
2011; Reddy et al., 2011). A total of 12 serum samples from these
patients and six additional samples from healthy controls were
used. Each individual sample was applied to the array under
the same conditions. None of the peptoids, with the exception
of the NMOP8 control, showed significant signal with any of
these samples above background, although it should be noted
that the background was quite high with two of the lupus
samples (Figure S4). Peptoid ADP3, which was used as a control
since it was previously reported to bind antibodies associated
with AD, showed clear binding for some of the AD samples (Fig-
ure S4). These data indicate that the peptoids identified in this
study are indeed selective ligands for NMO antibodies.
To determine the ability of the peptoids to accurately diagnose
NMOmore generally, we conducted an internally double-blinded
study of 15 serum samples. The samples were applied to the
array and called as NMO (N in Figure 4) or controls (C in Figure 4)
based on the intensities observed at each feature. Absolute fluo-
rescence intensity obtained for each peptoid hit on the blind
sample analysis is given in Table S2. A positive call entailed356 Chemistry & Biology 20, 351–359, March 21, 2013 ª2013 Elsevieobserving a signal on any of the peptoids, other than NMOP8,
that was above zero relative intensity or had a mean intensity
greater than 50% of the intensity of NMOP8. The relative inten-
sity was calculated by subtracting the mean intensity of each
compound from the overall median intensity. The calls were
then reported to the second individual, who then obtained the
key from the first technician to check the accuracy of the calls.
The data are shown in Figure 4 in the form of a heat map.
Beneath the map are the calls and the identities of the samples
revealed after unblinding, including if the NMO serum samples
tested positive or negative by the cell-killing assay (N+ or N).
The results showed that the panel of peptoids provides an accu-
rate diagnostic test for NMO. Fourteen of the 15 samples were
called correctly. Sample 15 was the exception. It was obtained
from an NMO patient whose serum tested negative in the cell-
killing assay. While peptoids NMOP2, NMOP4, and NMOP6
showed slight signals, these were very weak and did not pass
the criteria for calling the sample NMO. In the other 14 cases,
there was a very clear distinction between cases and controls,
including all four of the other samples that were obtained from
NMO patients whose antibodies did not mediate killing of
AQP4-expressing cells. Indeed, NMOP6 alone correctly pre-
dicted 13 of the 15 samples (two false negatives).
DISCUSSION
We previously reported a technology for the discovery of serum
biomarkers that involved comparative screens of the total
complement of circulating IgG antibodies from case and control
samples against a collection of synthetic, unnatural compounds
(peptoids) (Reddy et al., 2011). The goal was to identify com-
pounds that retain antibodies that are present in much higher
amounts in the serum of patients or animals with a particular
disease and thus would serve as useful serum biomarkers for
diagnosis. We validated this approach in experimental autoim-
mune encephalomyelitis, an animal model for MS induced by
immunization with a self-antigen peptide derived from myelin
oligodendrocyte glycoprotein (MOG). As anticipated, peptoids
that bound anti-MOG peptide antibodies were identified (Reddy
et al., 2011).
However, validation of this approach in a simple animal model
does not equate with efficacy in the far more complicated arena
of human disease. To address this issue, we performed a study
on sera from patients with AD. In a preliminary study of 54
patients, the same screening approach identified peptoids that
captured antibodies found only in AD patients, not age-matched
healthy controls or patients with Parkinson’s disease (Reddy
et al., 2011). However, because these putative AD biomarker
antibodies are novel, the results cannot be taken as clear
evidence of successful biomarker discovery until more extensive
validation trials are completed. These are in progress.
NMO provides an excellent opportunity to identify disease-
specific peptoid biomarkers in the context of an autoimmune
disorder with a known antigenic target, AQP4. There is a strong
expectation that application of this screening technology to
NMO should identify peptoids that bind to anti-AQP4 antibodies.
This was indeed the case. Peptoid NMOP6, one of several hits,
was clearly identified as a ligand for anti-AQP4 antibodies based
on its ability to bind amonoclonal anti-AQP4 antibody (Figure 2B)r Ltd All rights reserved
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depleted of anti-AQP4 antibodies by passage over immobilized
AQP4 (Figure 3).
Note that peptoid NMOP6 cannot possibly mimic a native
AQP4 epitope. In a peptoid, the side chains protrude from
the sp2-hybridized nitrogen, rather than the sp3-hybridized
a-carbon, of the main chain of the backbone. Moreover, most
of the side chains in NMOP6 do not correspond to those found
in proteins. Nonetheless, this relatively small molecule must
recognize some conserved feature of the antigen-binding sites
in some fraction of the anti-AQP4 polyclonal spectrum, although
in the absence of structural data it is impossible to speculate on
the detailed mode of binding.
From a preliminary blinded study (Figure 4), it appears that
peptoid NMOP6 and some of the other peptoid hits will be useful
as diagnostic reagents. NMOP6 alone was able to call 13 of the
15 samples correctly. The two misses were NMO samples that
tested negative in the cell-killing assay and thus might have
low levels of anti-AQP4 antibodies, although we cannot rule
out other explanations, as stated earlier. These were called as
false-negatives. Sample 15, as discussed earlier, showed
a very low signal, and sample 10 essentially showed only back-
ground signal. However, a moderate signal was observed on
NMOP5 for sample 10, allowing it to be called correctly. This
was the only peptoid in the group that captured significant
amounts of antibody from sample 10. Indeed, only peptoids
NMOP5 and NMOP6 would have been necessary to achieve
the 14/15 accuracy obtained in this initial study. NMOP2 and
NMOP9 also displayed significant signals for several of the
samples. Since these peptoids apparently bind different anti-
bodies than NMOP6, it is likely that, in larger studies, the use
of a four-peptoid panel might be advantageous. None of the
peptoids exhibited significant signals when presented to 18
other samples consisting of healthy controls and patients with
lupus, MS, narcolepsy, and AD (Figure S4). Lupus patients, in
particular, are known to have high levels of several circulating
autoantibodies, so this result supports the contention that the
peptoids identified in this study are indeed selective ligands for
NMO-related antibodies. Considering all of the samples
analyzed in this study, the diagnostic sensitivity of the assay is
93% and the diagnostic specificity is 100%. Note that, for all
of the samples, the signal obtained on the scrambled NMOP6s
peptoid was negligible and the signal on DNP was high,
providing useful negative and positive controls, respectively.
NMOP2, NMOP5, and NMOP9 may also bind to anti-AQP4
antibodies based on the serum depletion experiment (Figure 3),
but, if so, apparently to a different part of the polyclonal spectrum
of this antibody population. A detailed characterization of the
antibody-binding properties of these peptoids will require addi-
tional study.
Finally, it is noteworthy that this study used a second-genera-
tion screening technology different than the approach we have
published previously, which used peptoids displayed on micro-
arrays as the primary screening platform (Reddy et al., 2011).
Here, we used bead-displayed peptoids made by solid-phase
split-and-pool synthesis (Figliozzi et al., 1996). Whereas the mi-
croarray technology limits the number of molecules that can be
used in the primary screen to a few thousand, libraries of a few
million compounds can be made on beads (Alluri et al., 2003).Chemistry & Biology 20, 3Studies of peptide libraries have demonstrated that larger
libraries are more likely to contain high affinity ligands (Wilson
et al., 2001), so this technological advance may be useful in
the future for the discovery of superior antibody capture agents.
This type of screening protocol has been applied by us and
others to identify ligands for individual protein targets but not
for serum screening. A potential downside of this approach is
that it involves the sequential screening of pooled serum
samples (first control, then diseased), whereas the primary
microarray screens involved exposing several microarrays to
individual serum samples, both cases and controls, and identi-
fying peptoids that ‘‘lit up’’ when exposed to the diseased
samples, but not the controls. The danger of the pooling strategy
is that one or more, but not all, of the diseased serum samples
might contain high levels of antibodies that are idiosyncratic to
those individuals but not be related to the disease of interest.
In theory, if such antibodies were present at very high levels in
even a single person in the pool, one could identify peptoid
ligands to it that would be mistaken as capture agents for
disease-specific antibodies. Thus, it is critical to validate the
hits from the bead screen with several individual serum samples,
which we did here using the array platform. This might explain
why several of the peptoids that were identified as strong hits
in the bead screen did not capture significant amounts of pep-
toids from any of the NMO serum samples. Of course, there
could be technical reasons for this as well; for example, some
type of binding mode that is facilitated by the bead surface
but not the glass slide.
SIGNIFICANCE
The discovery of diagnostically useful serum biomarkers is
of great interest in translational science. In many diseases,
it is likely that an adaptive immune response produces
disease-specific antibodies that would be excellent candi-
dates for such biomarkers. However, a major impediment
to mining the immune system for useful biomarkers is the
assumption that only the native antigen will bind to
disease-specific antibodies with sufficient affinity and
selectivity to retain them from the serum and allow their
levels to be measured. The discovery of such antigens
has proven difficult in most diseases. We previously intro-
duced a different approach that involved the discovery of
synthetic ‘‘antigen surrogates’’ by comparative screening
of peptoid libraries against case and control sera (Reddy
et al., 2011). The utility of this approach was validated in
a simple mouse model for multiple sclerosis, and some
preliminary data were presented, indicating that this tech-
nique might also be applicable to the discovery of antibody
biomarkers for Alzheimer’s disease in humans. In this
study, we took advantage of the well-characterized autoim-
mune response against Aquaporin 4 (AQP4) in neuromyelitis
optica (NMO) patients to validate that this technology is
clearly applicable to human disease. A screen of 100,000
peptoids using a bead-based, sequential strategy yielded
several peptoids that bind antibodies present in NMO
patients but not in healthy controls or patients with multiple
sclerosis, lupus, Alzheimer’s disease, or narcolepsy. At
least one of these peptoids binds to anti-AQP4 antibodies.51–359, March 21, 2013 ª2013 Elsevier Ltd All rights reserved 357
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identification of serum antibody biomarkers in a human
disease.
EXPERIMENTAL PROCEDURES
Serum-Screening Protocol Using an OBOC Peptoid Library
The beads were swelled in N,N-dimethylformamide overnight, then washed
several times with water, and kept in water with gentle shaking for 12–15 hr fol-
lowed by equilibrating in Tris-buffered saline with 0.05% Tween 20 (TBST) for
at least 5 hr before screening.
To prescreen the library, we used serum samples from healthy people as
the control serum to prescreen the library to eliminate the beads binding to
the antibodies present in the healthy (normal control) serum samples. Six
different normal control (NC) sera were pooled in TBST. Enough buffer was
added to achieve a final total protein concentration of 100 mg/ml. The beads
(200 mg, preprocessed as described earlier) were incubated with 4 ml of NC
serum sample (100 mg/ml) at 4C overnight with gentle shaking. The beads
were washed three times with TBST and incubated with antihuman secondary
antibody conjugated with quantum dot (Qdot 655, Invitrogen; 20 ml in 4 ml
TBST) at room temperature (RT) for 2 hr. The beads were washed again three
times with TBST, and the red beads were removed under a fluorescent micro-
scope to get the denuded library. The remaining beads were washed several
times with TBST to screen against the disease serum.
The prescreened library was incubated with a pool of sera obtained from six
NMOpatients with high levels of anti-AQP4 Ab. The total protein concentration
was adjusted to 50 mg/ml total protein in 50% PBS Starting Block Buffer
(Thermo Scientific). The beads were incubated at 4C overnight by gentle
shaking. After the incubation step, the beads were washed three times with
TBST and treated with quantum dot-conjugated antihuman secondary anti-
body (Qdot 655; 20 ml in 4 ml TBST) at RT for 2 hr. The beads were washed
again with TBST three times and the beads with a red halo were collected
under a fluorescent microscope.
The hit beads were stripped off the antibody by heating in a 1%SDS solution
at 95C for 15 min and washed extensively with water before validating by re-
binding experiments using the same procedure described above.
Identification of the Compound
The antibody bound to the hit beads were stripped off by using 1% SDS solu-
tion at 95C, and the beads were washed extensively with water followed by
a 50% acetonitrile-water mixture. The beads were treated with CNBr (30 mg
CNBr in 1 ml cleaving cocktail solution, ACN:H2O:HOAc in the ratio 5:4:1) to
cleave the compound from the bead. The structure of the compounds was
then determined by tandem MALDI TOF-TOF mass spectrometry.
Antibody Depletion Experiment
Purified AQP4 protein was coupled to an amine-reactive protein immobiliza-
tion column (MicroLink Protein Coupling Kit, Thermo Scientific) following the
manufacturer’s protocol. The protein coupling efficiency was found to be
greater than 95%. Approximately 80–120 mg of protein was immobilized per
column. Serum samples were incubated with the AQP4-immobilized column
overnight at 4C to deplete the anti-AQP4 specific antibodies from the serum.
The experiment was repeated twice with the same serum samples to ensure
a complete depletion. Similarly, BSA immobilized column was used as a
control column in this experiment. These depleted serum samples were
used in microarray in appropriate dilution.
Microarray Spotting, Hybridization, and Data Analysis
A stock solution (500 mM) of the peptoid was prepared in 50%DMSOwith 50%
PBS and distributed in 384-well plates. All peptoids were shown to be
completely soluble in this spotting solution. Slideswere spotted on aNanoPrint
LM 60 (TeleChem International) with MP946Micro Spotting Pins. Spots gener-
ated were approximately 120 mm in diameter and were printed with a spot-to-
spot spacing of 375 mm. The pins were rinsed in between samples using two
cycles of wash (for 10 s) and sonication (for 10 s) in reservoirs containing
10% ethanol followed by drying under reduced pressure (for 10 s). The
slides were allowed to stand for at least 2 hr on the printer platform and stored358 Chemistry & Biology 20, 351–359, March 21, 2013 ª2013 Elsevieat 4C until use. Before incubation with the serum sample, the slides were
quenched with 100 mM cysteine in PBS (pH 7.2) for 20 min and washed
with deionized water.
The serum sample was diluted in a binding buffer (100 mM phosphate buf-
fer, pH 7.2, 150 mM NaCl, 10 mM EDTA) volume of 50 ml containing 0.25%
BSA, 0.01% Tween 20. The serum sample (4–10 mg/ml in total protein con-
centration, 50 ml) was applied to the array, and this was incubated at RT for
2 hr, washed first with 1 3 TBST (3 3 10 min) and then with deionized water
three times, and dried by centrifugation. Secondary antibody solution (Alexa
Fluor 647 goat antihuman IgG [H+L], Invitrogen, 1:1,500) in TBST with 0.25%
BSA was then applied, and the array was incubated at RT for 1 hr, washed
with 1 3 TBST (3 3 10 min), then deionized water three times and dried by
centrifugation.
Slides were scanned on a microarray scanner (GenePix 4200AL,
Molecular Devices) by using the 488/635 nm laser at 100% power and a 500-
photomultiplier-tube gain. All the scanned images were analyzed using
GenePix Pro 6.0 (Molecular Devices) software. The experiments were done
in triplicate, and each group of three included slides printed in different
batches to avoid bias due to batch-to-batch differences in the slides. Local
background subtracted mean (F635 mean  B635) spot intensities were
used for further analysis. These signal intensities were used for downstream
analysis using Excel software. The same criteria were used to analyze all the
test experiments on microarray.
Analysis of Blind Human Serum Samples
The blind human serum samples were analyzed in exactly the same way as
described earlier. Local background subtracted mean (F635 mean  B635)
spot intensities were used as net intensities. For the heat map, net intensity
was subtracted by overall F635 median and analyzed by TreeView (http://
rana.lbl.gov/EisenSoftware.htm) software.
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